Tectonic Therapeutic annual ebitda
2017
2018
2019
2020
2021
2022
2023
2024
2025
Tectonic Therapeutic EBITDA Growth & History (TECX)
Tectonic Therapeutic's calculated EBITDA was −$82.7M for fiscal 2025.
View full Tectonic Therapeutic company overviewTectonic Therapeutic annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$82.7M | −$26.3M | — |
| 2024 | 2024-12-31 | −$56.4M | −$13.2M | — |
| 2023 | 2023-12-31 | −$43.2M | $60.8M | — |
| 2022 | 2022-12-31 | −$104.0M | $13.4M | — |
| 2021 | 2021-12-31 | −$117.4M | $1.6M | — |
| 2020 | 2020-12-31 | −$119.0M | −$44.1M | — |
| 2019 | 2019-12-31 | −$75.0M | −$29.1M | — |
| 2018 | 2018-12-31 | −$45.9M | −$27.5M | — |
| 2017 | 2017-12-31 | −$18.3M | — | — |
Tectonic Therapeutic quarterly ebitda
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$23.9M | −$1.9M | — |
| Q1 2026 | 2026-03-31 | −$27.0M | −$9.1M | — |
| Q4 2025 | 2025-12-31 | −$21.2M | −$7.7M | — |
| Q3 2025 | 2025-09-30 | −$21.5M | −$2.3M | — |
| Q2 2025 | 2025-06-30 | −$22.0M | −$10.9M | — |
| Q1 2025 | 2025-03-31 | −$17.9M | −$5.3M | — |
| Q4 2024 | 2024-12-31 | −$13.5M | −$15.3M | — |
| Q3 2024 | 2024-09-30 | −$19.2M | −$9.5M | — |
| Q2 2024 | 2024-06-30 | −$11.1M | −$743,000 | — |
| Q1 2024 | 2024-03-31 | −$12.6M | $12.3M | — |
| Q4 2023 | 2023-12-31 | $1.8M | $26.7M | — |
| Q3 2023 | 2023-09-30 | −$9.7M | $12.9M | — |
| Q2 2023 | 2023-06-30 | −$10.3M | $17.1M | — |
| Q1 2023 | 2023-03-31 | −$24.9M | $4.1M | — |
| Q4 2022 | 2022-12-31 | −$24.9M | $2.6M | — |
| Q3 2022 | 2022-09-30 | −$22.6M | $9.6M | — |
| Q2 2022 | 2022-06-30 | −$27.4M | $3.7M | — |
| Q1 2022 | 2022-03-31 | −$29.0M | −$2.4M | — |
| Q4 2021 | 2021-12-31 | −$27.5M | $215,000 | — |
| Q3 2021 | 2021-09-30 | −$32.2M | $4.2M | — |
| Q2 2021 | 2021-06-30 | −$31.1M | −$2.5M | — |
| Q1 2021 | 2021-03-31 | −$26.6M | −$287,000 | — |
| Q4 2020 | 2020-12-31 | −$27.7M | −$4.6M | — |
| Q3 2020 | 2020-09-30 | −$36.4M | −$18.6M | — |
| Q2 2020 | 2020-06-30 | −$28.6M | −$12.1M | — |
| Q1 2020 | 2020-03-31 | −$26.3M | −$8.8M | — |
| Q4 2019 | 2019-12-31 | −$23.2M | −$6.7M | — |
| Q3 2019 | 2019-09-30 | −$17.8M | −$5.7M | — |
| Q2 2019 | 2019-06-30 | −$16.4M | −$6.9M | — |
| Q1 2019 | 2019-03-31 | −$17.5M | −$9.7M | — |
| Q4 2018 | 2018-12-31 | −$16.5M | — | — |
| Q3 2018 | 2018-09-30 | −$12.1M | −$5.7M | — |
| Q2 2018 | 2018-06-30 | −$9.5M | −$7.0M | — |
| Q1 2018 | 2018-03-31 | −$7.8M | — | — |
| Q3 2017 | 2017-09-30 | −$6.4M | — | — |
| Q2 2017 | 2017-06-30 | −$2.5M | — | — |
Tectonic Therapeutic ebitda trends
Over the last five fiscal years, Tectonic Therapeutic's ebitda increased from −$119.0M to −$82.7M, a change of $36.4M. The latest reported quarter, Q2 2026, shows −$23.9M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tectonic Therapeutic source filings ↗Community posts
Tectonic reports early safety data for vascular-disease antibody
Tectonic Therapeutic ($TECX) reported favorable Phase Ia safety findings for TX2100, an experimental antibody being developed for hereditary hemorrhagic telangiectasia, an inherited vascular disorder. Across six single-dose cohorts in healt ...
